Game Changer in Near Patient Diagnostics
Focused on Blood Coagulation

Inspired by Patients
Supported by Healthcare Workers, Payers and Pharma

Our ENZYPAD technology is bringing the lab to the patient, enabling diagnostic-based telemedicine and fast response in case of life-threatening bleeding.

Takeda and Enzyre to develop diagnostic device
(press 5 Dec. 2019)

Our technology will revolutionize
disease management

The ENZYPAD enables real near patient blood coagulation analysis, with the measured data being effortlessly made available to the treating physician irrespective of his/her physical location.

The ENZYPAD technology includes (a) a painless, easy to use blood sampling device; (b) a test specific single use microfluidic cartridge (“ENZYCARD”) that includes all necessary reagents and controls; and (c) a small hands-on re-useable processor (“ENZYPAD”) that enables the reagent flow, processes the test results and transfers those immediately to the cloud. The processor is controlled by an App on a mobile phone.

By transferring the data to the cloud, they can be made available to anyone with the appropriate authorization who can use them to efficiently manage the therapy of the patient.

Proud to be supported by an EFRO grant.

Powered by cutting
edge technology

The ENZYPAD technology uses proprietary innovative latent luciferin-protected peptide substrates to determine the activity of specific enzymes in the coagulation cascade. The enzymatic activity is directly proportional to the number of photons generated in the reaction chamber. These chemiluminescent signals are counted using highly sensitive optical sensors. One ENZYCARD (microfluidic cartridge) can run up to 16 individual reactions simultaneously, providing the health care professional with direct access to all the relevant data. All this is done starting from less than 100µL of whole blood collected though the specially developed blood collection device.

What this means:

For patients and their families: better quality of life

  • Certainty about their individual risk to develop a bleed
  • No need to travel to the clinic to manage their disease
  • Analysis can be performed when the need arises
  • Mental comfort: disease is under control
  • Less complications due to optimized treatment

For physicians and health care workers: data-based medicine

  • Can provide better care without additional effort
  • Can manage the patients anomaly based on patient real-time data
  • Can help more patients through telemedicine

For pharmaceutical companies: personalized medicine

  • Optimized therapy - increased customer satisfaction
  • Retain and/or increase market share
  • Increase the TAM for the therapy to regions where access to lab-based tests is limited

For insurance companies: lower costs and optimized treatment

  • Optimized therapy - less complications
  • Less hospital visits
  • One doctor can help more patients

Our dedicated team

Our team has over 60 years of experience in diagnostic development and world class expertise in blood coagulation. We are proud to have a Hemophilia A patient amongst our staff. His inspiration is fundamental in our dedication to make the right product.

Join us on our journey

Enzyre is now preparing to raise €10M in its Series A investment round.  The proceeds will be used to (a) finalize the development of the ENZYPAD en ENZYCARD Hemophilia A, (b) manufacture the portable instrument & disposable, and (c) perform studies to obtain regulatory approval in EU & US.  The product will be commercialized worldwide through our pharma partner. Interested candidate investors are encouraged to contact us at

Get involved